Literature DB >> 23562422

STAT signaling in different breast cancer sub-types.

Priscilla A Furth1.   

Abstract

This review summarizes information on expression of Signal Transducer and Activator of Transcription (STAT)s 1, 2, 3, 4, 5a/b and 6 in cancer cells from different human breast cancer sub-types. STAT proteins, especially STATs 1, 3 and 5a/b are expressed in some but not all cancers from all of the different major breast cancer sub-types. However, well-designed studies comparing expression patterns at the protein level in cancer and surrounding stromal cells are still needed to fully examine links with prognosis and therapeutic response. Moreover, it is not yet known if distinct expression patterns of STAT proteins could have dissimilar impacts in different sub-types, especially between the luminal A and B ER+ sub-types and the different TNBC sub-types. Recent data indicating that STAT 5 can be activated secondary to a therapeutic intervention and mediate resistance suggests that expression patterns should not only be examined in pre-treatment but also post-treatment samples from different sub-types.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer sub-types; ER; ER+ breast cancer; Estrogen Receptor; HER2; HER2 amplified breast cancer; IL; JAK; Janus Kinase; PI3K; STAT; Signal Transducer and Activator of Transcription; Signal Transducer and Activator of Transcription (STAT); TNBC; Triple Negative Breast Cancer; Triple negative breast cancer; human epidermal growth factor 2; interleukin; mTOR; mammalian target of rapamycin; phosphatidylinositol 3-kinase

Mesh:

Substances:

Year:  2013        PMID: 23562422      PMCID: PMC3740183          DOI: 10.1016/j.mce.2013.03.023

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  49 in total

1.  Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.

Authors:  Nills Diaz; Susan Minton; Charles Cox; Tammy Bowman; Tanya Gritsko; Roy Garcia; Ibrahim Eweis; Marek Wloch; Sandy Livingston; Ed Seijo; Alan Cantor; Ji-Hyun Lee; Craig A Beam; Daniel Sullivan; Richard Jove; Carlos A Muro-Cacho
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

Review 2.  Roles and regulation of stat family transcription factors in human breast cancer.

Authors:  Charles V Clevenger
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

3.  Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer.

Authors:  H Yamashita; M Nishio; Y Ando; Z Zhang; M Hamaguchi; K Mita; S Kobayashi; Y Fujii; H Iwase
Journal:  Endocr Relat Cancer       Date:  2006-09       Impact factor: 5.678

4.  Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b.

Authors:  Rebecca B Riggins; Keena S Thomas; Huy Q Ta; Jie Wen; Rebecca J Davis; Natasha R Schuh; Stacey S Donelan; Katherine A Owen; Matthew A Gibson; Margaret A Shupnik; Corinne M Silva; Sarah J Parsons; Robert Clarke; Amy H Bouton
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

5.  A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays.

Authors:  Colette Charpin; Véronique Secq; Sophie Giusiano; Séverine Carpentier; Lucile Andrac; Marie-Noëlle Lavaut; Claude Allasia; Pascal Bonnier; Stéphane Garcia
Journal:  Int J Cancer       Date:  2009-05-01       Impact factor: 7.396

6.  IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells.

Authors:  Wen Jie Zhang; Ben Hui Li; Xian Zi Yang; Pin Dong Li; Qin Yuan; Xiao Hong Liu; Shuang Bing Xu; Yan Zhang; Jia Yuan; Glenn S Gerhard; Kathryn K Masker; Cheng Dong; Walter A Koltun; Michael J Chorney
Journal:  Cytokine       Date:  2008-03-14       Impact factor: 3.861

7.  Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.

Authors:  Sun Young Kim; Hwang Phill Kim; Yu Jung Kim; Do Youn Oh; Seock-Ah Im; Dongsoon Lee; Hyun-Soon Jong; Tae-You Kim; Yung-Jue Bang
Journal:  Int J Oncol       Date:  2008-01       Impact factor: 5.650

Review 8.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

Authors:  Jeffrey S Ross; Elzbieta A Slodkowska; W Fraser Symmans; Lajos Pusztai; Peter M Ravdin; Gabriel N Hortobagyi
Journal:  Oncologist       Date:  2009-04-03

9.  Signal transducer and activator of transcription 1 in breast cancer: analysis with tissue microarray.

Authors:  Shyr-Ming Sheen-Chen; Chao-Cheng Huang; Rei-Ping Tang; Ching-Hsiang Yang; Fong-Fu Chou; Hock-Liew Eng
Journal:  Anticancer Res       Date:  2007 Jul-Aug       Impact factor: 2.480

10.  Signal transducer and activator of transcription-5 activation and breast cancer prognosis.

Authors:  Marja T Nevalainen; Jianwu Xie; Joachim Torhorst; Lukas Bubendorf; Philippe Haas; Juha Kononen; Guido Sauter; Hallgeir Rui
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

View more
  20 in total

Review 1.  Genetically engineered ERα-positive breast cancer mouse models.

Authors:  Sarah A Dabydeen; Priscilla A Furth
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

2.  EO771, the first luminal B mammary cancer cell line from C57BL/6 mice.

Authors:  Augustin Le Naour; Yvonne Koffi; Mariane Diab; Delphine Le Guennec; Stéphanie Rougé; Sahar Aldekwer; Nicolas Goncalves-Mendes; Jérémie Talvas; Marie-Chantal Farges; Florence Caldefie-Chezet; Marie-Paule Vasson; Adrien Rossary
Journal:  Cancer Cell Int       Date:  2020-07-20       Impact factor: 5.722

3.  Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study.

Authors:  Martha L Slattery; Abbie Lundgreen; Lisa M Hines; Gabriela Torres-Mejia; Roger K Wolff; Mariana C Stern; Esther M John
Journal:  Breast Cancer Res Treat       Date:  2014-08-08       Impact factor: 4.872

4.  Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation.

Authors:  Sachin K Deshmukh; Sanjeev K Srivastava; Arun Bhardwaj; Ajay P Singh; Nikhil Tyagi; Saravanakumar Marimuthu; Donna L Dyess; Valeria Dal Zotto; James E Carter; Seema Singh
Journal:  Oncotarget       Date:  2015-05-10

5.  Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, via STAT3 signaling.

Authors:  Ilenia Segatto; Stefania Berton; Maura Sonego; Samuele Massarut; Tiziana Perin; Erica Piccoli; Alfonso Colombatti; Andrea Vecchione; Gustavo Baldassarre; Barbara Belletti
Journal:  Oncotarget       Date:  2014-08-15

Review 6.  Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.

Authors:  Naveen K R Chalakur-Ramireddy; Suresh B Pakala
Journal:  Biosci Rep       Date:  2018-01-30       Impact factor: 3.840

7.  Systematic Identification and Assessment of Therapeutic Targets for Breast Cancer Based on Genome-Wide RNA Interference Transcriptomes.

Authors:  Yang Liu; Xiaoyao Yin; Jing Zhong; Naiyang Guan; Zhigang Luo; Lishan Min; Xing Yao; Xiaochen Bo; Licheng Dai; Hui Bai
Journal:  Genes (Basel)       Date:  2017-02-24       Impact factor: 4.096

8.  Predicting STAT1 as a prognostic marker in patients with solid cancer.

Authors:  Jinguo Zhang; Fanchen Wang; Fangran Liu; Guoxiong Xu
Journal:  Ther Adv Med Oncol       Date:  2020-05-08       Impact factor: 8.168

9.  Increased STAT1 signaling in endocrine-resistant breast cancer.

Authors:  Rui Huang; Dana Faratian; Andrew H Sims; Danielle Wilson; Jeremy S Thomas; David J Harrison; Simon P Langdon
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

Review 10.  Targeted therapies in breast cancer: New challenges to fight against resistance.

Authors:  Viviana Masoud; Gilles Pagès
Journal:  World J Clin Oncol       Date:  2017-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.